AboutContact us
dotsbydots
SEARCHCONTACT US

Buzz

Most popular

Daily
Weekly
1
Israel loses $1 billion Apache deal after failing to find $288 million in funding
2
Nvidia hits record $5.65 trillion as SpaceX seeks $40 billion to buy its AI chips
3
Israeli startup raises $5 million to rethink one of surgery's most invasive procedures
4
Israel to end private recruitment of construction workers from India and Sri Lanka
5
Foreign investors are pulling back from Israeli stocks as appetite for banks collapses
More news

Richard Francis

8 stories about Richard Francis
בניין חברת טבע בכפר סבא לצד מנכ"ל טבע ריצ'רד פרנסיס

Teva’s comeback is real. The harder part is still ahead

22.09.26|Sophie Shulman
The company has cleaned up its balance sheet and rebuilt its pipeline, but investors are still waiting to see whether the new strategy can deliver sustained growth.
ריצרד פרנסיס נשיא ו מנכל טבע

Teva’s $40 billion comeback brings Wall Street’s biggest prize into view

30.07.26|Sophie Shulman
After years as a struggling generic-drug giant, Teva’s transformation under Richard Francis has pushed its valuation above $40 billion and raised the possibility of joining the S&P 500.
בניין חברת טבע כפר סבא

The deal that signals Teva is back

30.04.26|Sophie Shulman
A calculated biotech acquisition and strong earnings revive confidence in the pharma giant.
ריצ'רד פרנסיס מפגש העיתונאים

Teva CEO cashes in $30 million in shares in two weeks

08.03.26|Sophie Shulman
Richard Francis sells stock after Teva’s 110% rally over the past year.
נשיא ומנכ"ל טבע ריצ'רד פרנסיס

After a threefold rally, Teva faces its next test

29.01.26|Sophie Shulman
Innovative drugs surge, but 2026 forecasts revive investor doubts.
מטה טבע כפר סבא

Teva surpasses expectations in Q4 but sets cautious outlook for 2025

29.01.25|Sophie Shulman
Despite a strong finish to the year, Teva forecasts lower-than-expected earnings and revenue growth for 2025.
ריצרד פרנסיס נשיא ו מנכל חברה חברת טב

Teva soars with double-digit growth in Q3, raises annual forecast

06.11.24|Sophie Shulman
Strong sales of Austedo and Ajovy push Teva’s revenues above expectations, with the company forecasting up to $16.5 billion in 2024.
מפגש עיתונאים ראשון עם נשיא ומנכל חברת טבע ריצ'רד פרנסיס

Teva CEO: "The company played not to lose, now we’ll play to win"

21.02.24|Sophie Shulman
Richard Francis' decision to focus on innovative drugs has boosted the stock by 40% since he took office. However, the high debt is still burdensome and the realization of the potential depends on the success of developments that are still in the laboratory